retatrutide type 2 diabetes trial results 2024 2025 💉 may be redefining obesity treatment. New data from TRIUMPH-1 showed: 🔥 ~28% average weight loss over 80 weeks 🔥 >30% weight loss in nearly half of participant #ObesityMedicine #Retatrutide #GLP1 #CardioMetabolic Michael Weintraub, MD on X:

The enhanced potency is due to the markedly decreased binding of Long-R3-IGF-I to IGF binding proteins which normally inhibit the biological actions of IGFs

J Endocrinol 264(2):e240210 McIntyre RS, Mansur RB, Rosenblat JD, Rhee TG, Cao B, Teopiz KM, Wong S, Le GH, Ho R, Kwan ATH (2025) Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase)

Por eso sus efectos son perifricos: sobre oxidacin de grasa, metabolismo energtico muscular y recuperacin, pero no sobre cognicin

In addition, it enhances the physiological production of melatonin, normalizes circadian rhythms, reduces cortisol levels, and stabilizes sex hormone secretion

Receptor Interactions and Molecular Targets Unlike many pharmacological agents with well-defined single receptor targets, BPC-157 appears to function through multiple cellular pathways and molecular interactions